124 results about "Amyloidosis" patented technology

The invention belongs to the technical field of modern agriculture, and particularly relates to a biocontrol bacillus amyloliquefaciens BA200 and application thereof. A new biological control bacterium BA200 is separated and identified, is named as bacillus amyloliquefaciens by taxonomy, and has a remarkable inhibition capability on two pathogenic bacteria, namely fusarium oxysporum and phytophthora vigna, causing the cowpea fusarium wilt, and the inhibition rate is up to 60% or above; fermentation liquor prepared from the bacillus amyloliquefaciens BA200 can remarkably reduce the morbidity and disease index of cowpea fusarium wilt, is a good biocontrol microorganism and has application and development potential and important significance in control of cowpea fusarium wilt, and the biocontrol bacterium bacillus amyloliquefaciens BA200 has a broad-spectrum biological control effect, can inhibit various phytopathogens and has a good application prospect. And valuable biocontrol bacterium resources are provided for preparation of biological bactericides.

The invention relates to bacillus amyloliquefaciens which is classified and named as bacillus amyloliquefaciens LDB1, the preservation number of the bacillus amyloliquefaciens is CCTCC No: M 20231897, and the preservation date is October 16, 2023. The invention relates to application of bacillus amyloliquefaciens in citrus waste compost. The invention relates to a microbial agent, which comprises bacillus amyloliquefaciens LDB1, bacillus amyloliquefaciens, bacillus subtilis and bacillus velezensis. The invention relates to application of a microbial agent in citrus waste compost. The method has the beneficial effects that lignin peroxidase, laccase and manganese peroxidase can be produced, good lignin degradation capability is achieved, degradation of lignocellulose in citrus waste compost can be effectively promoted by matching with other strains, the degradation rates of hemicellulose, cellulose and lignin are 33.8%, 36.5% and 38.5% respectively, and the method is suitable for industrial production. The strain and the microbial inoculum thereof have important application value in the aspect of recycling of high-lignin fiber organic wastes.

The present invention relates to tetracycline derivatives and their use as medicaments, in particular in the treatment or prevention of diseases selected from the group comprising or consisting of amyloidosis, pain, neurodegenerative diseases and neuroinflammatory diseases.

The invention provides a myocardial amyloidosis classification prediction method and system based on cardiac magnetic resonance multi-sequence radiomics, and is applied to the technical field of data processing. The method comprises the following steps: preprocessing cardiac magnetic resonance multi-sequence image information to generate a standardized multi-sequence image data set; processing the standardized multi-sequence image data set to generate a target image omics feature vector; processing the gene detection information to generate pathogenic gene characteristics and mutation type characteristics; processing the target radiomics feature vectors and the cardiac magnetic resonance parameters based on medical knowledge graph data to generate an AL type myocardial feature associated feature set and an ATTR type myocardial feature associated feature set; processing the blood detection index information and the intestinal microflora parameter information to generate myocardial amyloidosis influence factors; and processing the data based on the target myocardial amyloidosis classification prediction model to generate a myocardial amyloidosis classification prediction result.

The invention discloses a chemiluminescent probe of a targeted A beta oligomer as well as a preparation method and application of the chemiluminescent probe. The structural general formula of the chemiluminescent probe of the targeted A beta oligomer is shown as I in the specification. According to the present invention, the chemiluminescence probe capable of specifically targeting the A beta oligomer is successfully constructed for the first time so as to achieve the early diagnosis and treatment of AD; an additional light source is not needed, and background signals caused by exciting light can be effectively reduced, so that the detection sensitivity is higher. The chemiluminescent probe targeting the A beta oligomer can promote selective oxygenation of beta amyloid protein through chemical excitation and neutralize toxicity of the A beta oligomer, has certain treatment potential and is expected to be developed into an effective method for treating amyloidosis. # imgabs0 #

A method of pre-screening a human subject for a clinical trial for treatment of tauopathy or an amyloidogenic disease. The method comprises obtaining a plasma sample from the subject and determining a concentration of p217+tau present in the plasma sample. The method further comprises indicating the subject for further screening for the clinical trial when the concentration of p217+tau present in the plasma sample is greater than or equal to a minimum threshold and less than or equal to a maximum threshold. The minimum threshold corresponds to an amount of p217+tau in plasma over which subjects present with mild cognitive impairment (MCI) and an increased accumulation of tau tangles in the brain as compared to a cognitively normal patient. The maximum threshold corresponds to an amount of p217+tau present in plasma over which subjects present with pathology of widespread accumulation of tau tangles in multiple regions of the brain.

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.

Provided herein are anti-TTR antibody dosing regimens useful for the treatment of thyroxine transporter amyloid cardiomyopathy (ATTR-CM) in adult patients. In an embodiment, the patient is treated with an anti-TTR antibody comprising NI006 / ALXN2220.

The present invention features compositions and methods for preventing or treating neuroinflammation, amyloidopathy or tauopathy by inhibiting Acyl-CoA:Cholesterol Acyltransferase activity, in particular with brain-permeable inhibitors encapsulated in a stealth liposome-based nanoparticle. Stealth liposome-based nanoparticles for reducing or attenuating amyloidopathy or tauopathy are also provided.

The invention provides a prediction method and device for diagnosing myocardial amyloidosis, and is applied to the technical field of data processing. The method comprises the steps of performing data cleaning processing on a first training sample set to generate a second training sample set; performing missing value supplement processing on the second training sample set to generate a target training sample set; processing a preset myocardial amyloidosis prediction model based on the target training sample set and the verification sample set to generate a target myocardial amyloidosis prediction model; processing the clinical parameter information of the target user to generate target physiological parameter information; processing the living habit information of the target user to generate a dynamic risk adjustment factor; the target physiological parameter information and the dynamic risk adjustment factor are processed based on the target myocardial amyloidosis prediction model, early warning information is generated, and the early warning information is used for representing the relevance between the target user and myocardial amyloidosis, hypertrophic cardiomyopathy and hypertension left ventricular hypertrophy.

The invention relates to methods of treating subjects that would benefit from reduction in expression of transthyretin (TTR), such as subjects having a TTR-associated disease, disorder, or condition, e.g., transthyretin-mediated amyloidosis, or Stargardt disease, using double-stranded ribonucleic acid (dsRNA) compositions targeting the TTR gene. The invention also provides methods for preventing at least one symptom in a subject having a TTR-associated disease, disorder, or condition, e.g., transthyretin-mediated amyloidosis, or Stargardt disease.

To provide antibody formulations useful for treatment of patients with AL amyloidosis.SOLUTION: Provided herein are methods of treating a Mayo Stage IV patient with AL amyloidosis, comprising administering an effective dosage of birtamimab. In some embodiments, the method reduces the risk of mortality in the patient. In some embodiments, the method reduces the risk of all-cause mortality in the patient. In some embodiments, the method of treatment reduces the risk of cardiac mortality in the patient.SELECTED DRAWING: None

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.

The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.

The invention relates to a conjugate for transferring an effector molecule from outside a cell into said cell, the conjugate comprising at least one effector molecule to be transferred into the cell, at least one saponin of the mono-desmosidic triterpene glycoside type or the bi-desmosidic triterpene glycoside type, and at least one single-domain antibody (sdAb), covalently bound to each other, wherein the sdAb is capable of binding to a cell-surface molecule of said cell. The invention also relates to a pharmaceutical composition comprising the conjugate of the invention. Furthermore, the invention relates to a pharmaceutical composition of the invention, for use as a medicament. In addition, the invention relates to a pharmaceutical composition of the invention, for use in the treatment or the prophylaxis of any one or more of: a cancer, an auto-immune disease such as rheumatoid arthritis, an enzyme deficiency, a disease related to an enzyme deficiency, a gene defect, a disease relating to a gene defect, an infection such as a viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, an amyloidosis and transthyretin-mediated amyloidosis. The invention also relates to an in vitro or ex vivo method for transferring the conjugate from outside a cell to inside said cell or for transferring the effector molecule comprised by the conjugate of the invention from outside a cell to inside said cell, preferably to the cytosol of said cell.

The invention discloses a myocardial amyloidosis quantitative analysis method based on SPECT imaging and related equipment, and relates to the field of wisdom medical device.The method comprises the steps that firstly, three-dimensional SPECT original data of N time phases of a target patient in the cardiac cycle are collected, a mu graph is generated based on low-dose CT for registration and attenuation correction, and a dynamic image is reconstructed; and then an MR structure sequence under synchronous electrocardio gating is obtained, and SPECT and MR space standardization and partial volume effect correction processing are completed. And unifying the cardiac cycle image form through affine and nonlinear transformation, and generating a high-quality enhanced SPECT image. Finally, radioactive counting information is extracted on the basis of three-dimensional segmentation, multiple myocardial quantitative indexes are calculated, comprehensive analysis of myocardial functions is achieved in combination with left ventricular functional parameters, and accurate image support is provided for non-invasive diagnosis and curative effect evaluation of myocardial amyloidosis.

The present invention relates to peptides that have preventive, ameliorative, or therapeutic effects against amyloidosis and / or macular degeneration, are safe for living organisms, and have few side effects including abnormal reactions, as well as pharmaceutical compositions and health functional foods containing the same.

Tetracycline derivatives and their use as a medicament. In particular, the tetracycline derivatives may be used in the treatment or the prevention of a disease, such as amyloidosis, pain, neurodegenerative diseases and neuroinflammatory diseases, in which the tetracycline derivatives or pharmaceutical compositions including these compounds are administered to a subject in need thereof.

The present invention relates to compositions and methods for treating diseases and / or disorders associated with protein aggregates. By expressing a chimeric antigen receptor (CAR) in a monocyte, macrophage or dendritic cell, the modified cell is recruited or applied to the tissue microenvironment where it acts as a potent immune effector by infiltrating the tissue and eliminating, reducing, inhibiting or preventing protein aggregation. Other aspects of this invention include methods and pharmaceutical compositions comprising the CAR modified monocyte, macrophage or dendritic cell for treating a condition, such as a neurodegenerative disease / disorder, an inflammatory disease / disorder, a cardiovascular disease / disorder, a fibrotic disease / disorder and amyloidosis.

A peptide-based vaccine for use in the treatment or prevention of amyloid-to-thyroid amyloidosis (ATTR) is provided.

The present invention concerns multifunctional antibody construct containing at least one antibody Ab and two distinct payloads D1 and D2 of structure (1) or (2). Wherein L1, L2, L3, L4 and L5 are linkers; x1 and x2 are each individually an integer in the range of 1-8, wherein x1+x2=2-10; BM is a branching moiety; m and n are each independently 0 or 1; x3 is an integer in the range of 1-4; and D1 and D2 are two distinct payloads selected from the group consisting of polypeptides, small molecules, cytotoxins and oligonucleotides, wherein at least one of D1 and D2 is a polypeptide. The multifunctional antibody construct according to invention are suitable for use in medicine, such as for use in the treatment of cancer, a viral infection, a bacterial infection, a neurological disease, an autoimmune disease, an eye disease, hypercholesterolemia and amyloidosis.

The present disclosure relates in some aspects to methods and compositions for detecting amyloid-related diseases in an individual.

The present invention relates to a cultivation method for improving the survival rate of clownfish seedlings, including aquaculture water and equipment management, fertilized egg hatching treatment, larval stage cultivation management, and juvenile stage cultivation management. The specific operations include the following contents: (1) aquaculture water and equipment management, including the preparation of aquaculture water and the treatment of aquaculture equipment; (2) fertilized egg hatching treatment; (3) larval stage cultivation management, including water change management, bait feeding management, drug prevention, and aeration management; (4) juvenile stage cultivation management; and (5) juvenile stage cultivation management. The present invention performs differentiated aquaculture management on clownfish seedlings at different growth stages, and by adjusting the aquaculture environment, water quality, and feeding feed at each cultivation stage, effectively prevents and treats amyloidosis and dinoflagellate disease, and reduces damage to the fish body caused by other parasites and fungi; thereby ensuring a clean living environment for the clownfish and effectively improving the survival rate of the clownfish.

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.

Immunotherapy for musculoskeletal disorders and conditions associated with transthyretin amyloidosis is provided.

Transthyretin (TTR) is a soluble protein involved in thyroxine and retinol transport in the body. Under certain conditions, the TTR protein adopts a misfolded, misassembled, and / or aggregated TTR conformation, which can be toxic and lead to transthyretin-mediated amyloidosis (ATTR). Provided herein, inter alia, are compositions (e.g., pharmaceutical compositions) containing anti-TTR antibodies or antigenic fragments thereof, and related articles of manufacture. Further provided herein, inter alia, are methods for treating or preventing ATTR using the pharmaceutical compositions described herein.

The present disclosure relates to heterogeneous cell compositions derived from canine or feline uterine tissue and methods of producing and use thereof. In some aspects, the heterogeneous cell compositions comprise a mixture of mesenchymal progenitor cells and epithelial progenitor cells. In some aspects, the heterogeneous cell compositions are used as an autologous or allogeneic treatment for the treatment of diseases such as chronic kidney disease, atopic dermatitis, immune mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune mediated polyarthritis or wounds in canines and felines.

The present disclosure relates to methods useful to identify subjects having an increased risk for conversion to mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and / or stage a subject prior to the onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and / or identify subjects with Aβ amyloidosis and / or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.